Iradimed Corporation, a leader in innovative medical devices for magnetic resonance imaging (MRI)-compatible patient monitoring and infusion systems, has announced a board transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after providing valuable strategic guidance during a period of significant growth and innovation for the company.
Effective September 2, 2025, the board has appointed Joe Kiani, the founder of Masimo Corporation and renowned medical technology innovator and entrepreneur, to fill the vacancy on the board. Kiani brings with him a distinguished track record in medical technology, having served as chairman and CEO of Masimo Corporation from 1989 until 2024, growing the company into a global leader in non-invasive patient monitoring technologies, particularly pulse oximetry.
Kiani is also the CEO of Willow Laboratories, a health and wellness innovator, and Like Minded Labs, a company focused on advanced video technologies. He serves on the board of directors of CDx Medical Technologies, an early-stage respiratory care company, and brings critical expertise to the board with over 500 patents or patent applications and a reputation for driving innovation.
Upon joining the board, Kiani will serve on the board’s audit committee and as chairman of the compensation committee, helping to guide Iradimed’s growth in the medical device sector.
Iradimed Corporation designs, manufactures, markets, and distributes MRI-compatible medical devices, accessories, disposables, and related services. They are known for providing a non-magnetic intravenous infusion pump system specifically designed to be safe for use during MRI procedures, as well as an MRI-compatible patient vital signs monitoring system.
The company's patented Mridium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures.
Their 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room.
The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering, wireless SpO2 using Masimo® algorithms, non-magnetic respiratory CO2, invasive and non-invasive blood pressure, patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous minimum alveolar concentration measurements.
The transition in the board of directors brings a change in leadership and expertise to the company, as it continues to advance its mission of delivering innovative MRI-compatible solutions to improve patient care. Today the company's shares have moved -1.14% to a price of $71.615. For more information, read the company's full 8-K submission here.
